Despite the proven role of IL-17 in IBD and SpA pathogenesis, a clinical trial has shown that, contrary to expectations, anti-IL-17 therapy by Sekukinumab aggravated the course of Crohn’s disease, so the trial has been stopped [121]. Here, IL17A is linked to inflammatory bowel disease.